Genscript Biotech Co. (OTCMKTS:GNNSF – Get Free Report)’s stock price traded up 46.5% during trading on Friday . The company traded as high as C$2.93 and last traded at C$2.93. Approximately 9,078 shares were traded during trading, an increase of 61% from the average daily volume of 5,631 shares. The stock had previously closed at C$2.00.
Genscript Biotech Stock Up 46.5%
The stock’s fifty day simple moving average is C$1.71 and its 200-day simple moving average is C$1.64.
About Genscript Biotech
GenScript Biotech Corporation is a global contract research, development and manufacturing organization (CDMO) specializing in synthetic biology and biopharmaceutical services. Founded in 2002, the company provides end-to-end solutions that span gene and peptide synthesis, recombinant protein expression, custom antibody discovery and cell line development. GenScript’s integrated platforms support early-stage discovery through to process development, enabling academic institutions, biotech innovators and pharmaceutical companies to accelerate research timelines.
The company’s core offerings include molecular biology services such as DNA construction, gene editing using CRISPR/Cas9 technology and high-throughput peptide libraries.
Further Reading
- Five stocks we like better than Genscript Biotech
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Genscript Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genscript Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
